Physician profile
Jonathan S Leibowitz
NPI 1588665012
$5,456.96
in general payments reported to CMS, 2019-2025
28 companies · $2,855 in 2025
The $2,855 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $576 · 2020: $404 · 2021: $554 · 2022: $377 · 2023: $109 · 2024: $582 · 2025: $2,855.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,876 · Consulting Fee: $1,650 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,876.14 |
| Consulting Fee | $1,650.00 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,985.47 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $780.29 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $580.12 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $408.98 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $236.29 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $211.86 | 2024-2025 | Cologuard Collection Kit |
| Abbvie INC. | $176.64 | 2021-2025 | |
| Dexcom, INC. | $130.87 | 2025 | Dexcom G6 Transmitter |
| Hologic Sales and Service, LLC | $125.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $123.09 | 2019 | |
| Glaxosmithkline, LLC. | $71.86 | 2022-2024 | Trelegy Ellipta |
| Abbott Laboratories | $70.08 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $69.58 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.15 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $60.09 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $41.08 | 2021-2025 | Vpriv |
| Janssen Pharmaceuticals, INC | $36.91 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $36.61 | 2024-2025 | Jynarque |
| Genzyme Corporation | $36.31 | 2022 | |
| Medtronic, INC. | $34.26 | 2025 | Pipeline |
| Allergan, INC. | $31.03 | 2019 | |
| Eisai INC. | $28.82 | 2025 | |
| Seqirus USA INC | $27.73 | 2025 | Flucelvax |
| Bayer Healthcare Pharmaceuticals INC. | $19.62 | 2023 | |
| Alfasigma USA, INC. | $17.31 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.41 | 2022 | |
| Amgen INC. | $16.36 | 2024 | Repatha, Otezla |
| E.R. Squibb & Sons, L.L.C. | $15.14 | 2025 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Leibowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.